Literature DB >> 7802861

In vitro activity of DMG-Mino and DMG-DM Dot, two new glycylcyclines, against anaerobic bacteria.

C E Nord1, A Lindmark, I Persson.   

Abstract

The in vitro activity of DMG-Mino and DMG-DM Dot against 350 anaerobic bacterial strains including anaerobic cocci, Propionibacterium acnes, Clostridium perfringens, Clostridium difficile, Bacteroides fragilis, other Bacteroides species and fusobacteria was determined by the agar dilution method. Their activity was compared with that of minocycline, doxycycline, piperacillin, cefoxitin, imipenem, clindamycin and metronidazole. DMG-Mino and DMG-DM Dot and imipenem were the most active agents tested. DMG-Mino and DMG-DM Dot had in vitro activity superior to that of minocycline and doxycycline.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7802861     DOI： 10.1007/bf02098471

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  1 in total

1.  Antibiotic susceptibility of anaerobic bacteria with special reference to Bacteroides fragilis.

Authors:  K Dornbusch; C E Nord; B Olsson-Liljeqvist
Journal:  Scand J Infect Dis Suppl       Date:  1979
  1 in total
  5 in total

1.  Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci.

Authors:  D B Hoellman; G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

2.  In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).

Authors:  P J Petersen; N V Jacobus; W J Weiss; P E Sum; R T Testa
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

3.  In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria.

Authors:  M L van Ogtrop; D Andes; T J Stamstad; B Conklin; W J Weiss; W A Craig; O Vesga
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

4.  Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance.

Authors:  I Chopra; M Roberts
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

5.  Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.

Authors:  C M Salvatore; C Techasaensiri; C Tagliabue; K Katz; N Leos; A M Gomez; G H McCracken; R D Hardy
Journal:  Antimicrob Agents Chemother       Date:  2009-01-12       Impact factor: 5.191
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.